{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:05:54Z","timestamp":1792148754101,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1038\/ncpgasthep0517","type":"journal-article","created":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T10:18:41Z","timestamp":1149243521000},"page":"338-348","source":"Crossref","is-referenced-by-count":21,"title":["Therapy Insight: management of hepatorenal syndrome"],"prefix":"10.1038","volume":"3","author":[{"given":"Andr\u00e9s","family":"C\u00e1rdenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpgasthep0517_CR1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V  et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164\u2013176","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","volume":"350","author":"P Gin\u00e8s","year":"2004","unstructured":"Gin\u00e8s P  et al. (2004) Management of cirrhosis and ascites. N Engl J Med 350: 1646\u20131654","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0517_CR3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","volume":"119","author":"E Akriviadis","year":"2000","unstructured":"Akriviadis E  et al. (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 1637\u20131648","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00042737-199909000-00004","volume":"11","author":"K Moore","year":"1999","unstructured":"Moore K (1999) Renal failure in acute liver failure. Eur J Gastroenterol Hepatol 11: 967\u2013975","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0517_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gines","year":"1993","unstructured":"Gines A  et al. (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105: 229\u2013236","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","volume":"41","author":"C Alessandria","year":"2005","unstructured":"Alessandria C  et al. (2005) MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 41: 1282\u20131289","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"5","author":"P Sort","year":"1999","unstructured":"Sort P  et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 5: 403\u2013409","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0517_CR8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9343(70)80073-0","volume":"49","author":"M Epstein","year":"1970","unstructured":"Epstein M  et al. (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49: 175\u2013185","journal-title":"Am J Med"},{"key":"BFncpgasthep0517_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier RW  et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151\u20131157","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"BFncpgasthep0517_CR10","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","volume":"43","author":"Y Iwakiri","year":"2006","unstructured":"Iwakiri Y and Groszmann R (2006) The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (Suppl 1): S121\u2013S131","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR11","first-page":"43","volume-title":"Ascites and renal dysfunction in liver disease","author":"M Bernardi","year":"2005","unstructured":"Bernardi M and Domenicali M (2005) The renin\u2013angiotensin\u2013aldosterone system in cirrhosis. In Ascites and renal dysfunction in liver disease, 43\u201353 (Eds Gin\u00e8s P  et al.) Oxford, UK: Blackwell Publishing"},{"key":"BFncpgasthep0517_CR12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/9780470987476.ch5","volume-title":"Ascites and renal dysfunction in liver disease","author":"F Dudley","year":"2005","unstructured":"Dudley F and Esler M (2005) The sympathetic nervous system in cirrhosis. In Ascites and renal dysfunction in liver disease, 54\u201372 (Eds Gin\u00e8s P  et al.) Oxford, UK: Blackwell Publishing"},{"key":"BFncpgasthep0517_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.2003.01647.x","volume":"58","author":"S Ishikawa","year":"2003","unstructured":"Ishikawa S and Schrier RW (2003) Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58: 1\u201317","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"BFncpgasthep0517_CR14","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0168-8278(03)00007-2","volume":"38","author":"V Arroyo","year":"2003","unstructured":"Arroyo V and Colmenero J (2003) Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38 (Suppl 1): S69\u2013S89","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR15","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2005.09.024","volume":"129","author":"C Terra","year":"2005","unstructured":"Terra C  et al. (2005) Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 129: 1944\u20131953","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","volume":"42","author":"L Ruiz-del-Arbol","year":"2005","unstructured":"Ruiz-del-Arbol L  et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42: 439\u2013447","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/jhep.2003.50447","volume":"38","author":"W Ruiz-del-Arbol","year":"2003","unstructured":"Ruiz-del-Arbol W  et al. (2003) Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38: 1210\u20131218","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/hep.20832","volume":"42","author":"K Lenz","year":"2005","unstructured":"Lenz K (2005) Hepatorenal syndrome\u2014is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 42: 263\u2013265","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR19","first-page":"305","volume-title":"Ascites and renal dysfunction in liver disease","author":"A C\u00e1rdenas","year":"2005","unstructured":"C\u00e1rdenas A and Gin\u00e8s P (2005) Management of hyponatremia in cirrhosis. In Ascites and renal dysfunction in liver disease, 305\u2013314 (Eds Gin\u00e8s P  et al.) Oxford, UK: Blackwell Publishing"},{"key":"BFncpgasthep0517_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archinte.1994.00420020117013","volume":"154","author":"L Caregaro","year":"1994","unstructured":"Caregaro L  et al. (1994) Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 154: 201\u2013205","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep0517_CR21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1053\/ajkd.2003.50035","volume":"41","author":"D Sherman","year":"2003","unstructured":"Sherman D  et al. (2003) Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41: 269\u2013278","journal-title":"Am J Kidney Dis"},{"key":"BFncpgasthep0517_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2005.40952.x","volume":"100","author":"A C\u00e1rdenas","year":"2005","unstructured":"C\u00e1rdenas A (2005) Hepatorenal syndrome: a dreaded complication of end-stage liver disease. Am J Gastroenterology 100: 1\u20138","journal-title":"Am J Gastroenterology"},{"key":"BFncpgasthep0517_CR23","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","volume":"94","author":"P Gin\u00e8s","year":"1998","unstructured":"Gin\u00e8s P  et al. (1998) Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94: 1493\u20131502","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","volume":"20","author":"A Follo","year":"1994","unstructured":"Follo A  et al. (1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20: 1495\u20131501","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2036.2006.02706.x","volume":"23","author":"P Angeli","year":"2006","unstructured":"Angeli P  et al. (2006) Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 23: 75\u201384","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0517_CR26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/jhep.2001.27830","volume":"34","author":"A C\u00e1rdenas","year":"2001","unstructured":"C\u00e1rdenas A  et al. (2001) Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis. Hepatology 34: 671\u2013676","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.20373","volume":"40","author":"M Guevara","year":"2004","unstructured":"Guevara M  et al. (2004) Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40: 646\u2013651","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR28","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/j.1572-0241.2002.05920.x","volume":"97","author":"K Watt","year":"2002","unstructured":"Watt K  et al. (2002) Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 97: 2046\u20132050","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0517_CR29","first-page":"543A","volume":"42","author":"L Servin-Abad","year":"2005","unstructured":"Servin-Abad L  et al. (2005) Retrospective analysis of 140 patients labeled as hepatorenal syndrome in a referral center [abstract]. Hepatology 42: 543A","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.20829","volume":"42","author":"J Fernandez","year":"2005","unstructured":"Fernandez J  et al. (2005) A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42: 627\u2013634","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/9780470987476.ch22","volume-title":"Ascites and renal dysfunction in liver disease","author":"A Rimola","year":"2005","unstructured":"Rimola A  et al. (2005) Liver transplantation for patients with cirrhosis and ascites. In Ascites and renal dysfunction in liver disease, 271\u2013285 (Eds Gin\u00e8s P  et al.) Oxford, UK: Blackwell Publishing"},{"issue":"Suppl 1","key":"BFncpgasthep0517_CR32","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.jhep.2004.12.007","volume":"42","author":"A C\u00e1rdenas","year":"2005","unstructured":"C\u00e1rdenas A and Gin\u00e8s P (2005) Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 42 (Suppl 1): S124\u2013S133","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","volume":"40","author":"T Restuccia","year":"2004","unstructured":"Restuccia T  et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case\u2013control study. J Hepatol 40: 140\u2013146","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR34","first-page":"1753","volume":"50","author":"G Testino","year":"2003","unstructured":"Testino G  et al. (2003) Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent\u2013shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50: 1753\u20131755","journal-title":"Hepatogastroenterology"},{"key":"BFncpgasthep0517_CR35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","volume":"47","author":"KA Brensing","year":"2000","unstructured":"Brensing KA  et al. (2000) Long-term outcome after transjugular intrahepatic portosystemic stent\u2013shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47: 288\u2013295","journal-title":"Gut"},{"key":"BFncpgasthep0517_CR36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","volume":"14","author":"C Alessandria","year":"2002","unstructured":"Alessandria C  et al. (2002) Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 14: 1363\u20131368","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0517_CR37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/9780470987476.ch28","volume-title":"Ascites and renal dysfunction in liver disease","author":"V Arroyo","year":"2005","unstructured":"Arroyo V  et al. (2005) Hepatorenal syndrome in cirrhosis: clinical features, diagnosis, and management. In Ascites and renal dysfunction in liver disease, 341\u2013359 (Eds Gin\u00e8s P  et al.) Oxford, UK: Blackwell Publishing"},{"key":"BFncpgasthep0517_CR38","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P  et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690\u20131697","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0168-8278(90)90106-2","volume":"11","author":"J Fevery","year":"1990","unstructured":"Fevery J  et al. (1990) Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 11: 153\u2013158","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0168-8278(05)80042-X","volume":"17","author":"A Gines","year":"1993","unstructured":"Gines A  et al. (1993) Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 17: 220\u2013226","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(96)91667-0","volume":"347","author":"CP Soper","year":"1996","unstructured":"Soper CP  et al. (1996) Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 347: 1842\u20131843","journal-title":"Lancet"},{"key":"BFncpgasthep0517_CR42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(05)74933-3","volume":"353","author":"S Holt","year":"1999","unstructured":"Holt S  et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353: 294\u2013295","journal-title":"Lancet"},{"key":"BFncpgasthep0517_CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","volume":"27","author":"M Guevara","year":"1998","unstructured":"Guevara M  et al. (1998) Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27: 35\u201341","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","volume":"30","author":"V Gulberg","year":"1999","unstructured":"Gulberg V  et al. (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30: 870\u2013875","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","volume":"29","author":"A Hadengue","year":"1998","unstructured":"Hadengue A  et al. (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29: 565\u2013570","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","volume":"33","author":"J Uriz","year":"2000","unstructured":"Uriz J  et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33: 43\u201348","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR47","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","volume":"122","author":"R Moreau","year":"2002","unstructured":"Moreau R  et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122: 923\u2013930","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega R  et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. Hepatology 36: 41\u201348","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR49","first-page":"15","volume":"64","author":"JP Mulkay","year":"2001","unstructured":"Mulkay JP  et al. (2001) Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 64: 15\u201319","journal-title":"Acta Gastroenterol Belg"},{"key":"BFncpgasthep0517_CR50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","volume":"14","author":"C Halimi","year":"2002","unstructured":"Halimi C  et al. (2002) Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 14: 153\u2013158","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0517_CR51","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","volume":"17","author":"I Colle","year":"2002","unstructured":"Colle I  et al. (2002) Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17: 882\u2013888","journal-title":"J Gastroenterol Hepatol"},{"key":"BFncpgasthep0517_CR52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","volume":"18","author":"P Solanki","year":"2003","unstructured":"Solanki P  et al. (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152\u2013156","journal-title":"J Gastroenterol Hepatol"},{"key":"BFncpgasthep0517_CR53","first-page":"78","volume":"9","author":"F Saner","year":"2004","unstructured":"Saner F  et al. (2004) Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 9: 78\u201382","journal-title":"Eur J Med Res"},{"key":"BFncpgasthep0517_CR54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/00042737-200308000-00015","volume":"15","author":"FH Saner","year":"2003","unstructured":"Saner FH  et al. (2003) Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gastroenterol Hepatol 15: 925\u2013927","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"BFncpgasthep0517_CR55","first-page":"81","volume":"42","author":"LL Gluud","year":"2005","unstructured":"Gluud LL  et al. (2005) Terlipressin for hepatorenal syndrome. The Cochrane Database of Systematic Reviews J Hepatol 42 (Suppl 2): 81","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong F  et al. (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55\u201364","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","volume":"36","author":"C Duvoux","year":"2002","unstructured":"Duvoux C  et al. (2002) Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36: 374\u2013380","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR58","first-page":"19","volume-title":"Update in Treatment of Liver Disease","author":"V Arroyo","year":"2005","unstructured":"Arroyo V  et al. (2005) Circulatory dysfunction in cirrhosis. In Update in Treatment of Liver Disease, 19\u201328 (Eds Arroyo V  et al.) Barcelona: Ars Medica"},{"key":"BFncpgasthep0517_CR59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","volume":"38","author":"G Pomier-Layrargues","year":"2003","unstructured":"Pomier-Layrargues G  et al. (2003) Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 38: 238\u2013243","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20559","volume":"41","author":"TD Boyer","year":"2005","unstructured":"Boyer TD and Haskal Z (2005) The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41: 386\u2013400","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR61","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","volume":"28","author":"M Guevara","year":"1998","unstructured":"Guevara M  et al. (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28: 416\u2013422","journal-title":"Hepatology"},{"key":"BFncpgasthep0517_CR62","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/j.gastro.2005.07.031","volume":"129","author":"G D'Amico","year":"2005","unstructured":"D'Amico G  et al. (2005) Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129: 1282\u20131293","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0517_CR63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2005.06.005","volume":"43","author":"A Albillos","year":"2005","unstructured":"Albillos A  et al. (2005) A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 43: 990\u2013996","journal-title":"J Hepatol"},{"key":"BFncpgasthep0517_CR64","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1081\/JDI-200035988","volume":"26","author":"RK Kapling","year":"2004","unstructured":"Kapling RK and Bastani B (2004) The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 26: 563\u2013568","journal-title":"Ren Fail"},{"key":"BFncpgasthep0517_CR65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/08860229509026250","volume":"17","author":"F Keller","year":"1995","unstructured":"Keller F  et al. (1995) Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 17: 135\u2013146","journal-title":"Ren Fail"},{"key":"BFncpgasthep0517_CR66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/lv.2000.6355","volume":"6","author":"SR Mitzer","year":"2000","unstructured":"Mitzer SR  et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6: 277\u2013286","journal-title":"Liver Transpl"},{"key":"BFncpgasthep0517_CR67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000086552","volume":"23","author":"K Rifai","year":"2005","unstructured":"Rifai K  et al. (2005) The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23: 298\u2013302","journal-title":"Blood Purif"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0517","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:03:10Z","timestamp":1684440190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BFncpgasthep0517"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0517","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}